{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-034737","form_type":"8-K","ticker":"GCTK","cik":"0001506983","company_name":"Glucotrack, Inc.","filed_at":"2024-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.302761+00:00","generated_at":"2026-05-31T06:36:49.814564+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Glucotrack appoints CEO Paul Goode and biotech veteran John Ballantyne to Board of Directors","bullets":["CEO Paul V. Goode appointed as a board member, effective August 27, 2024.","John Ballantyne, former Aldevron co-founder and CSO, appointed to board effective immediately.","Ballantyne brings 20+ years biotech experience; served as CSO through Danaher acquisition.","Ballantyne's background expected to aid commercialization of Glucotrack's implantable CGM technology."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-034737","json":"https://secwatch.observer/filing/0001493152-24-034737.json","markdown":"https://secwatch.observer/filing/0001493152-24-034737.md","text":"https://secwatch.observer/filing/0001493152-24-034737.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506983/000149315224034737/0001493152-24-034737-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506983/000149315224034737/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:36:49.814564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"35e6f37e4b","claim":"Paul V. Goode was appointed as director at Glucotrack, Inc..","evidence_excerpt":"On August 27, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Paul V. Goode, and Mr. John Ballantyne to the Board of Directors (the “Board”) as board members.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315224034737/0001493152-24-034737-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"9fc13a5250","claim":"John Ballantyne was appointed as director at Glucotrack, Inc..","evidence_excerpt":"On August 27, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Paul V. Goode, and Mr. John Ballantyne to the Board of Directors (the “Board”) as board members.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315224034737/0001493152-24-034737-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}